Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with cystic fibrosis—an outcome William Blair found “potentially promising.” ...

In a mixed interim data drop, Arcturus Therapeutics has revealed a lack of efficacy for its investigational inhaled mRNA therapy in cystic fibrosis (CF). The findings, shared today before market open, ...

Arcturus stock sinks 56% after cystic fibrosis drug shows no clear lung function gains. Phase 2 data finds ARCT-032 safe but lacking strong efficacy signals so far. Company plans higher-dose, 12-week ...

Sept 23 (Reuters) - Biotech company Arcturus Therapeutics (ARCT.O), opens new tab sued AbbVie (ABBV.N), opens new tab in California federal court on Tuesday for allegedly stealing trade secrets ...

Arcturus Therapeutics is transitioning from COVID-era revenues to milestone-driven growth, led by its mRNA platform and strategic partnerships. KOSTAIVE, ARCT's self-amplifying mRNA COVID-19 vaccine, ...

Shannon Silverman, an Astrophysicist at the Clay Center in Charleston West Virginia, guides us through the cosmos above West Virginia. In this episode she tells us about some of the summer's brightest ...

Arcturus Therapeutics is scaling back work on early-stage candidates and will instead dedicate its resources to its more developed mRNA therapies, the biotech announced Tuesday alongside its ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work in an effort to prioritize spending and extend its cash runway. In a brief ...

SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease ...